CytoHub Inc.
June 22, 2026
Type: Company Presentation
Focus Area:
Cardiovascular
CytoHub: Transforming Cardiac Development
CytoHub is an AI-driven cardiac biology platform company delivering human-relevant models and predictive insights that de-risk and accelerate cardiac drug and digital health development. The company generates revenue today through CardioVive and BioEngineAI, serving biopharma, digital health, and advanced research partners with earlier, more reliable decisions in cardiac discovery, safety, and translation.
CytoHub selectively advances therapeutics through platform leverage. HeartReady is being transitioned into Cardia Therapeutics, a separately capitalized subsidiary or joint venture, preserving platform focus while isolating clinical and regulatory risk.
Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
(HeartReady™): Platform-enabled, hypo-immune cardiac cell therapy
CEO
Rajib Biswas, PhD
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
Two to three years.
What is your next catalyst (value inflection) update?
IND Submission
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}